Initial TNF-α Levels Predict Infliximab Response in Pediatric Crohn's Disease
• A recent study reveals that initial levels of TNF-α can predict the treatment response to Infliximab (IFX) in pediatric Crohn's Disease (CD).
• Higher initial TNF-α concentrations correlate with lower IFX trough concentrations, potentially leading to suboptimal therapeutic effects.
• A TNF-α cutoff value of 27.6 pg/mL was identified, above which higher IFX doses may be needed to maintain therapeutic concentrations.
• Measuring initial cytokine levels could help personalize IFX dosing strategies, improving treatment outcomes for pediatric CD patients.
© Copyright 2025. All Rights Reserved by MedPath